Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(6):490; doi:10.1093/jnci/djk101
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Carter, H. B.
Right arrow Articles by Metter, E. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Carter, H. B.
Right arrow Articles by Metter, E. J.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

CORRESPONDENCE

Response: Re: Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of Curability

H. Ballentine Carter, Luigi Ferrucci, Anna Kettermann, Patricia Landis, James Wright, Jonathan I. Epstein, Bruce J. Trock, E. Jeffrey Metter

Affiliations of authors: James Buchanan Brady Urological Institute (HBC, PL, JW, BJT) and Department of Pathology (JIE), Johns Hopkins School of Medicine, Baltimore, MD; National Institute on Aging, NIA-ASTRA Harbor Hospital, Baltimore, MD (LF, AK, EJM)

Correspondence to: H. Ballentine Carter, MD, James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, 600 North Wolfe St, Marburg Building, Rm 145, Baltimore, MD 21287 (e-mail: hcarter@jhmi.edu).

The first 10% of the full text of this article appears below.

Our recommendation that prostate-specific antigen velocity (PSAV) be part of a decision algorithm for prostate biopsy referral is based on observations that include a current approach to prostate-specific antigen testing that has resulted in the serendipitous discovery of many cancers that otherwise would have remained undetected (1). The standard approach to biopsy referral based on an absolute PSA threshold has resulted in no treatment benefit for the majority of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of Curability
Ruth D. Etzioni, Donna P. Ankerst, and Ian M. Thompson
J Natl Cancer Inst 2007 99: 489-490. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
R. D. Etzioni, D. P. Ankerst, N. S. Weiss, L. Y. T. Inoue, and I. M. Thompson
Is Prostate-Specific Antigen Velocity Useful in Early Detection of Prostate Cancer? A Critical Appraisal of the Evidence
J Natl Cancer Inst, October 17, 2007; 99(20): 1510 - 1515.
[Abstract] [Full Text] [PDF]